Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Sezary syndrome
Stage/Subtype:  stage II mycosis fungoides/Sezary syndrome
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 41 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 0761-010, NCI-2012-02782, NCT01728805
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Age: 65 and under
Trial IDs: CB-AB006, NCI-2013-00758, 2012-0166, NCT01854567
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Dasatinib in Treating Patients with Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated with Autologous Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA-180-381, NCI-2012-00767, 1203010693, 2011-203, NCT01609816
Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-180-384, NCI-2012-00773, 2011-204, NCT01643603
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: BP-HM-001, NCI-2013-00518, NCT01744223
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Romidepsin and Lenalidomide in Treating Patients with Relapsed or Refractory Lymphoma or Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-170, NCI-2013-00005, NCT01755975
Brentuximab Vedotin and Rituximab in Treating Patients with Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
Carfilzomib, Romidepsin, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell and T-cell Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-179, NCI-2015-00109, NCT02341014
Donor Transplant, Total Lymphoid Irradiation, and Antithymocyte Globulin in Treating Patients with Cutaneous T Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: BMT206, NCI-2011-00855, SU-04062009-2138, NCT00896493
Bortezomib and Vorinostat as Maintenance Therapy after Autologous Stem Cell Transplant in Treating Patients with Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2292.00, NCI-2009-01302, X05287, NCT00992446
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Two Step Donor Stem Cell Transplant in Treating Patients With High-Risk Hematological Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 08D.85, NCI-2012-00407, 2007-61, NCT01315132
Brentuximab Vedotin in Treating Patients with Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0914, NCI-2011-01045, NCT01352520
Busulfan and Fludarabine Phosphate in Treating Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2011-0958, NCI-2012-00573, NCT01572662
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Chemotherapy, Stem Cell Transplant, and Romidepsin in Treating Patients with T-cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: Over 16
Trial IDs: 13-020, NCI-2013-01365, NCT01908777
Combination Chemotherapy before Peripheral Blood Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 201312115, NCI-2013-02212, NCT01969435
Ixazomib in Treating Patients with Relapsed or Refractory Cutaneous or Peripheral T-cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2014.031, NCI-2014-02244, HUM00088647, X16038, NCT02158975
Romidepsin and Lenalidomide in Treating Patients with Previously Untreated Peripheral T-Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14H04, NCI-2014-01770, RV-CL-PTCL-PI-003974, STU00097620, NCT02232516
Start Over